IbaĆez, Edna P.
HRN: 01-73-85 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/25/2022
CO-AMOXICLAV 625MG (TAB)
04/25/2022
04/29/2022
PO
625mg
BID X 5 More Days
On Going UTI Treatment; Pus Cells: TNTC; Bacteria: Moderate
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes